| 000 | 01665cam a2200325 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223030608.0 | ||
| 008 | 120326s2012 ua d f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.08.08.M.Sc.2012.Ib.P | ||
| 100 | 0 | _aIbrahim Salah Ibrahim | |
| 245 | 1 | 0 |
_aPharmaceutical and bio pharmaceutical studies on menindione in different dosage forms / _cIbrahim Salah Ibrahim ; Supervised Mahmoud M. Ghorab |
| 246 | 1 | 5 | _aدراسة صيدلية و بيو صيدلية لعقار المنينديون و ذلك فى أشكال صيدلية مختلفة |
| 260 |
_aCairo : _bIbrahim Salah Ibrahim , _c2012 |
||
| 300 |
_a104 P. : _bcharts ; _c25cm |
||
| 502 | _aThesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics | ||
| 520 | _aPhytomenadione is a procoagulant factor. As a component of a hepatic carboxylase system. Phytomenadione is involved in carboxylation of clotting factors II (prothrombin). VII , IX and X , and of clotting inhibitors protein C and protein S in the postribosmal phase. Coumarins inhibit the reduction of Phytomenadione (quinone form) to Phytomenadione hydroquinone and also prevent the phytomenadione epoxide arising after the carboxylation reaction from being reduced to the quinone form | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aB-cyclodextrin | |
| 653 | 4 | _aMenindione | |
| 653 | 4 | _aPhytomenadione | |
| 700 | 0 |
_aMahmoud Mohamed Ghorab , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSamia _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c38005 _d38005 |
||